Real world evidence of PD-L1, TMB prevalence and efficacy of 1st line chemotherapy in these high or low population for stage IV urothelial cancer

Trial Identifier: D419BR00014
Sponsor: AstraZeneca
NCTID:: NCT04052113
Start Date: October 2019
Primary Completion Date: March 2020

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Japan Kyoto-shi, Japan, 606-8507